Based on the current stage of clinical development and estimated trial completion dates registered on ClinicalTrials.gov, a realistic earliest possible timeline might be considered as follows: 20252026: Completion of key phase 3 TRIUMPH trial data 20262027: Potential regulatory submission to the MHRA (and FDA/EMA in parallel) 20272028: Possible MHRA marketing authorisation, subject to satisfactory review 2028 onwards: NICE technology appraisal and potential NHS commissioning decision These timelines are speculative and depend on multiple variables, including trial outcomes, the completeness of the regulatory submission, MHRA review timelines, and NICE deliberations
The goal is to encourage the powder to fully dissolve
And that really would hurt the overall system
Encrypted-messaging-only contact, refusal to share a COA, no verifiable US presence or physical business address, crypto-only or anonymous-payment checkout, or purity claims with no supporting data are all reasons to walk away
Kwong LK, Mockett RJ, Bayne ACV, Orr WC, Sohal RS
Exercise Programs